loading…
D81.39 Other adenosine deaminase deficiency
BackD81Combined immunodeficienciesCategory10 →D81.0Severe combined immunodeficiency [SCID] with reticular dysgenesisCategoryD81.1Severe combined immunodeficiency [SCID] with low T- and B-cell numbersCategoryD81.2Severe combined immunodeficiency [SCID] with low or normal B-cell numbersCategoryD81.3Adenosine deaminase [ADA] deficiencyCategory4 →D81.30Adenosine deaminase deficiency, unspecifiedCategoryD81.31Severe combined immunodeficiency due to adenosine deaminase deficiencyCategoryD81.32Adenosine deaminase 2 deficiencyCategoryD81.39Other adenosine deaminase deficiencyCategoryD81.4Nezelof's syndromeCategoryD81.5Purine nucleoside phosphorylase [PNP] deficiencyCategoryD81.6Major histocompatibility complex class I deficiencyCategoryD81.7Major histocompatibility complex class II deficiencyCategoryD81.8Other combined immunodeficienciesCategory3 →D81.81Biotin-dependent carboxylase deficiencyCategory3 →D81.810Biotinidase deficiencyCategoryD81.818Other biotin-dependent carboxylase deficiencyCategoryD81.819Biotin-dependent carboxylase deficiency, unspecifiedCategoryD81.82Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]CategoryD81.89Other combined immunodeficienciesCategoryD81.9Combined immunodeficiency, unspecifiedCategory
CategoryCODABLE
D81.39
Other adenosine deaminase deficiency
EXAMPLES
Adenosine deaminase [ADA] deficiency type 1, NOS
Adenosine deaminase [ADA] deficiency type 1, without SCID
Adenosine deaminase [ADA] deficiency type 1, without severe combined immunodeficiency
Partial ADA deficiency (type 1)
Partial adenosine deaminase deficiency (type 1)
Adenosine deaminase [ADA] deficiency type 1, without SCID
Adenosine deaminase [ADA] deficiency type 1, without severe combined immunodeficiency
Partial ADA deficiency (type 1)
Partial adenosine deaminase deficiency (type 1)
- Chapter
- III · Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Section
- D80-D89
- Valid from
Source
CMS ICD-10-CM Tabular List, edition FY2026.